The global drug-induced immune hemolytic anemia market, valued at approximately USD 7.8 billion in 2023, is poised for substantial growth and is projected to reach USD 13.4 billion by 2033. This anticipated growth, at a steady CAGR of 5.6% over the forecast period, is being fueled by several key trends and developments in the biotechnology …